Are taxane based regimens better than non-taxane fluoropyrimidine based regimens in advanced gastric cancer? Findings from an observational multicentre study, South India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20210418Keywords:
Carboplatin, CMOG, Paclitaxel, Radiological response, Survival, SORT IT, ToxicityAbstract
Background: Capecitabine, 5 Fluorouracil, platinum agents and taxanes are either used alone or in combination in advanced gastric cancers (AGC). Data on tolerability and efficacy of these regimens are minimal. We aimed to report proportion of AGC patients opting for best supportive care upfront and tolerability and efficacy of taxane and non-taxane fluoropyrimidine based regimens from three oncology centers, South India.
Methods: Case records of AGC patients initiated on either taxane or non-taxane fluoropyrimidine based chemotherapy during May 2016 to Dec 2017 in three private tertiary cancer care centers across two states in south India were reviewed. Information on clinical characteristics, regimen used, radiological and clinical response, toxicity and its related hospital admissions were extracted. Statistical analysis was done by categorical variables that were summarized using proportions. Median survival was calculated using Kaplan Meier curves and comparison between the groups were done using log-rank test.
Results: Of 88 AGC patients, 27 patients (30.7%) opted for best supportive care; 19 and 41 patients received paclitaxel based and non-taxane fluoropyrimidine based regimens respectively. There was no statistically significant difference in pain symptoms, vomiting, hospital admissions and intensive care admissions between the two regimens. Median (inter quartile range) survival of patients receiving best supportive care, taxane based regimen and non-taxane fluoropyrimidine regimen were 3.1 (1.5-16.1), 7.4 (1.6-15.0) and 11.6 (3.2-29.3) months respectively. Median (range) survival on any chemotherapy was 10.3 (1.6-29.3) months and it was significantly higher compared to best supportive care (p<0.001)
Conclusions: AGC patients on chemotherapy had improved overall survival compared to stand alone best supportive care. Fluoropyrimidine based regimens offered better survival than taxane based regimen.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver.2013;7:385-93.
Cutsem EV, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654-64.
Al-Batran SE, Jäger E, Scholz M. Chemotherapy for advanced gastric cancer. J Clin Oncol. 2007;25:729
Barad AK, Mandal SK, Harsha HS, Sharma BM, Singh TS. Gastric cancer-a clinicopathological study in a tertiary care centre of North-eastern India. J Gastrointest Oncol. 2014;5:142-7.
Nandi A, Sinha S, Biswas P, Kar M. Clinicopathological profile of gastric cancer in a tertiary care hospital in Eastern India: A prospective 2 year study. Clin Cancer Investig J.2014;4:14.
Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543-8.
Glimelius B, Hoffman K, Haglund U, Nyrén O, Sjödén PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994;5(2):189-90.
Shi J, Gao P, Song Y, Chen X, Li Y, Zhang C, et al. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis. Sci Rep. 2017;7(1):5319.
Souza FDO, Carlos L, Antunes M, Humberto L. Review article palliative treatment of gastric adenocarcinoma. 2011;24:74-80.
Cutsem EV. The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 2004;9(2):9-15.
Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20:1635-49.
Bittoni A, Maccaroni E, Scartozzi M, Berardi R, Cascinu S. Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. Eur Rev Med Pharmacol Sci. 2010;14.
Wöhrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Annals of oncology. 2004;15:1585-95.
Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, et al. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7:123-33.
Kang B, Kwon O-K, Chung H, Yu W, Kim J, Kang BW, et al. Taxanes in the treatment of advanced Gastric Cancer. Molecules. 2016;21:651.
Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Filho SC, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced Gastric, or Gastroesophageal Adenocarcinoma. J Clin Oncol 2005;23:5660-7.
Cutsem EV, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7.
Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver. 2013;7:385-93.
Bishop L, dougherty L, bodenham A, mansi J, crowe P, kibbler c, et al. Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol 2007;29:261-78.
Yi M, Kim I-R, Choi E-K, Lee S, Kwak M, Cho J, et al. Discomfort related to peripherally inserted central catheters in cancer patient. Asian Oncol Nurs. 2017;17:229.
Bouza E, Burillo A, Muñoz P. Catheter-related infections: diagnosis and intravascular treatment. Clin Microbiol Infect. 2002;8:265-74.
Ganguly s, biswas b, ghosh j, dabkara d. metastatic gastric cancer: real world scenario from a developing country. South Asian J Cancer. 2018;7:171.
Bhat G. Retrospective study of oxaliplatin, leucovarin and 5 fluoruracil regimen in patients with advanced gastric cancer with poor performance status: A study at a tertiary center of South India. South Asian J cancer. 2018;7:223-5.
Servarayan Murugesan C, Manickavasagam K, Chandramohan A, Jebaraj A, Jameel ARA, Jain MS, et al. Gastric cancer in India: epidemiology and standard of treatment. Updates Surg 2018;70:233-9.
26. Prithviraj GK, Baksh K, Fulp W, Meredith K, Hoffe S, Shridhar R, et al. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. Dis Esophagus. 2015;28:782-7.
Bittoni A, Scartozzi M, Giampieri R, Faloppi L, Bianconi M, Mandolesi A, et al. Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. PLoS One. 2013;8:78544.
Prithviraj GK, Baksh KA, Fulp WJ, Meredith KL, Hoffe SE, Shridhar R, et al. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. J Clin Oncol. 2014;32(15):15070.
Shi J, Gao P, Song Y, Chen X, Li Y, Zhang C, Wang H, Wang Z. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis. Scientific reports. 2017;7:5319.
Chen X-L, Chen X-Z, Yang C, Liao Y-B, Li H, Wang L, et al. Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e60320.
Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, Ajani JA. Advanced gastric adenocarcinoma: optimizing therapy options. Expert Rev Clin Pharmacol. 2017;10:263-71.
Babu K, Chaudhuri T, Lakshmaiah K, Dasappa L, Jacob L, Babu M, et al. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. Indian J Cancer. 2017;54:47.
Maji S, Saha ML, Kanwar KS, Das S. An epidemiological study of 50 consecutive cases of gastric cancer from a tertiary care hospital in West Bengal. Int Surg J. 2016;2:247-51.
Kabir MA, Barua R, Masud H, Ahmed DS, Islam MM, Karim E, Sarker MN, Barman RC. Clinical presentation, histological findings and prevalence of Helicobacter pylori in patients of gastric carcinoma. Faridpur Medical College J. 2011;6:78-81.
Shrikhande S, Parikh P, Pautu J, Patil P, Chilukuri S, Ganesh B, et al. Indian Council of Medical Research consensus document for the management of gastric cancer. Indian J Med Paediatr Oncol. 2014;35:239.
Sushma J, Kartheek BVS, Lakshmi AB. Clinicopathological study of carcinoma stomach over a period of 5 years. Int J Res Med Sci. 2017;5:558.
Al-Saleh K, El-Sherify M, Bedair A, Nazmy N, Elbasmi A, Hussein A, et al. Clinicopathological criteria and prognostic factors in gastric adenocarcinoma in Kuwait. J Glob Oncol 2018;4(2):80.
Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239-48.
Qurieshi MA, Masoodi MA, Kadla SA, Ahmad SZ, Gangadharan P. Gastric cancer in kashmir. Asian Pac J Cancer Prev. 2011;12:303–7.
Ibrahim M, Gilbert K. Management of gastric cancer in Indian population. Transl Gastroenterol Hepatol. 2017;2:64.
Yu X, Hu F, Li C, Yao Q, Zhang H, Xue Y. Clinicopathologic characteristics and prognosis of proximal and distal gastric cancer. Onco Targets Ther. 2018;11:1037-44.
Yu X, Hu F, Li C, Yao Q, Zhang H, Xue Y. Clinicopathologic characteristics and prognosis of proximal and distal gastric cancer. Onco Targets Ther. 2018;11:1037.
Chavan SS. Spectrum of gastric neoplastic lesions: A Clinicopathological study in the region of North Karnataka. 3:20.
Kayal S, Pani C kumar, Biswajit D, Verma S, Sistla SC, Cyriac SL. Comparison of efficacy and safety of capecitabine and oxaliplatin (CAPOX) with epirubicin, oxaliplatin plus capecitabine (EOX) as first line treatment for advanced gastric cancer (AGC), a randomized clinical study. J Clin Oncol 2015; 33(15):15026.
Shin SJ, Chun SH, Kim KO, Kim MK, Lee KH, Hyun MS, Bae SH, Ryoo HM, Do YR, Kwon KY, Song HS. The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study. The Korean journal of internal medicine. 2005;20:135.
Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): An open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:277-87.
Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, et al. Medical management of gastric cancer: a 2017 update. Cancer Med. 201;7(1):123-33.
Haller D, Misset J. Docetaxel in advanced gastric cancer. Anticancer Drugs. 2002;13.
Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology-williston park then huntington the melville new york 2002;6(6):89-96.
Iizumi S, Takashima A, Narita Y, Tajika M, Muro K, Kawai S, et al. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study. Cancer Chemother Pharmacol. 2017 ;80:575-82.
Sastre J, Garcia-Saenz JA, Diaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol. 2006;12:204-13.
Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, et al. Phase II Study of Paclitaxel and Carboplatin in Patients With Advanced Gastric Cancer. Am J Clin Oncol. 2003;26:37-41
